Temsirolimus (CCI-779): Early results of an mTOR inhibitor in renal carcinoma

被引：0
|
作者：
Hudes, GR [1 ]
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：18 / 18
页数：1
相关论文
共 50 条
  • [1] Temsirolimus: CCI 779, CCI-779, Cell cycle inhibitor-779
    不详
    [J]. Drugs in R & D, 2004, 5 (6) : 363 - 367
  • [2] Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients
    Peralba, JM
    DeGraffenried, L
    Friedrichs, W
    Fulcher, L
    Grünwald, V
    Weiss, G
    Hidalgo, M
    [J]. CLINICAL CANCER RESEARCH, 2003, 9 (08) : 2887 - 2892
  • [3] Irradiation enhances mammalian target of rapamycin (mTOR)-targeted glioblastoma therapy with CCI-779 (temsirolimus)
    Weiler, M.
    Pfenning, P-N
    Thiepold, A-L
    Jestaedt, L.
    Berger, B.
    Combs, S.
    Bendszus, M.
    Wick, W.
    [J]. ONKOLOGIE, 2010, 33 : 60 - 60
  • [4] Effects of mTOR inhibitor, rapamycin and the ester analogue CCI-779 on rhabdomyosarcoma.
    Wan, XL
    Kalburgi, S
    Heiman, L
    [J]. CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6179S - 6179S
  • [5] The novel mTOR inhibitor CCI-779 (temsirolimus) induces antiproliferative effects through inhibition of mTOR in Bel-7402 liver cancer cells
    Li, Shuyu
    Liang, Yan
    Wu, Manlin
    Wang, Xiaojing
    Fu, Haixia
    Chen, Yuhao
    Wang, Zhigang
    [J]. CANCER CELL INTERNATIONAL, 2013, 13
  • [6] Irradiation-enhanced mammalian target of rapamycin (mTOR)-targeted glioblastoma therapy with CCI-779 (temsirolimus)
    Weiler, M.
    Pfenning, P. -N.
    Thiepold, A. -L.
    Jestaedt, L.
    Berger, B.
    Bendszus, M.
    Wick, W.
    [J]. EJC SUPPLEMENTS, 2009, 7 (04): : 37 - 38
  • [7] Activity of the mammalian target of rapamycin inhibitor temsirolimus (CCI-779) in relapsed mantle cell lymphoma
    不详
    [J]. CLINICAL LYMPHOMA, 2004, 5 (03): : 144 - 145
  • [8] The mTOR inhibitor, CCI-779, is effective against myeloma growth in vivo.
    Frost, P
    Gera, J
    Shi, YJ
    Lichtenstein, A
    [J]. BLOOD, 2003, 102 (11) : 445A - 445A
  • [9] The novel mTOR inhibitor CCI-779 (temsirolimus) induces antiproliferative effects through inhibition of mTOR in Bel-7402 liver cancer cells
    Shuyu Li
    Yan Liang
    Manlin Wu
    Xiaojing Wang
    Haixia Fu
    Yuhao Chen
    Zhigang Wang
    [J]. Cancer Cell International, 13
  • [10] Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer
    Chan, S
    Scheulen, ME
    Johnston, S
    Mross, K
    Cardoso, F
    Dittrich, C
    Eiermann, W
    Hess, D
    Morant, R
    Semiglazov, V
    Borner, M
    Salzberg, M
    Ostapenko, V
    Illiger, HJ
    Behringer, D
    Bardy-Bouxin, N
    Boni, J
    Kong, S
    Cincotta, M
    Moore, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) : 5314 - 5322
12345